# Robert Adelman

> Robert Adelman is a Series A investor at venBio Partners backing Medical and Health Care. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [venBio Partners](https://shizune.co/investors/profile/venbio)
- Location: San Francisco, United States
- Total investments: 3
- Last investment: Jun 2018
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/bobadelmandivorcelaw

Robert Adelman is a Series A investor at venBio Partners in San Francisco focused on Medical and Health Care. Robert J. Adelman is a Managing Partner at venBio Partners.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 67% |
| Health Care | 2 | 67% |
| Genetics | 1 | 33% |
| CleanTech | 1 | 33% |
| Biotechnology | 1 | 33% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 33% |
| Series B | 1 | 33% |
| Series C | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Precision BioSciences | Precision BioSciences is a biotechnology company dedicated to improving lives through its next-generation gene editing technology, ARCUS.Precision BioSciences’ mission is to translate the world’s most powerful genome editing technology into greatly needed products throughout the life sciences. Precision’s proprietary ARCUS genome editingtechnology enables the production of highly specific nucleases that can insert, remove, and modify DNA at essentially any location in a complex genome. | $110M | Series B | Jun 08, 2018 |  |
| Precision BioSciences | Precision BioSciences is a biotechnology company dedicated to improving lives through its next-generation gene editing technology, ARCUS.Precision BioSciences’ mission is to translate the world’s most powerful genome editing technology into greatly needed products throughout the life sciences. Precision’s proprietary ARCUS genome editingtechnology enables the production of highly specific nucleases that can insert, remove, and modify DNA at essentially any location in a complex genome. | $25.7M | Series A | May 11, 2015 |  |
| CryoCor | CryoCor, Inc. is a medical technology company headquartered in San Diego, California developing products that use cryogenic technology to treat cardiac rhythm disorders called arrhythmias. Cardiac cryoablation is a non-surgical, minimally-invasive procedure in which a cardiologist inserts a catheter into a blood vessel in the leg of an afflictedindividual and advances it into the heart. Once it reaches the targeted cardiac tissue, the catheter tip temperature is lowered to approximately -90°C — thereby blocking the conduction of the abnormal signals causing the heart to beat inappropriately and restoring its function to normal.The CryoCor™ Cardiac Cryoablation System consists of a cryoablation catheter that is connected to an articulating arm mounted on the company’s refrigeration console. To facilitate catheter placement, the System can be used in conjunction with CryoCor introducer sheaths.The System has been approved for use in Europe and has been commercially available there since 2002. CryoCor's European activities are managed by its wholly-owned subsidiary in Cologne, Germany which directs the company's marketing, sales and post-market clinical activities. The CryoCor Cardiac Cryoablation System is currently in use at multiple medical centers throughout Europe. | $27.5M | Series C | Jun 06, 2003 |  |

3 of 3 investments shown.

## Co-investors
- [Amgen Ventures](https://shizune.co/investors/profile/amgen-ventures) — VC Fund, 2 deals together
- [The Longevity Fund](https://shizune.co/investors/profile/the-longevity-fund) — VC Fund, 2 deals together
- [Adage Capital Management](https://shizune.co/investors/profile/adage-capital-management) — VC Fund, 1 deal together
- [Agent Capital](https://shizune.co/investors/profile/agent-capital) — VC Fund, 1 deal together
- [Aliment Capital](https://shizune.co/investors/profile/aliment-capital) — VC Fund, 1 deal together
- [ArrowMark Partners](https://shizune.co/investors/profile/arrowpoint-partners) — VC Fund, 1 deal together

## About venBio Partners

VC Fund · San Francisco, United States

venBio invests in promising companies at various stages: from early to late stage, and from academic startups to spinouts. We tend to lead most of our investments, and we enjoy building syndicates and teams.We are mindful of potential acquisition partners from the outset, and we ensure that our companies are best positioned to meet theirrequirements. This includes IP, CMC, and the details of clinical trials, including indication, trial design, endpoints, powering, and regulatory considerations. Our team’s expertise and involvement helps companies make a bigger impact, and this leads to impactful and lasting relationships with the leaders that we work with.

4 contacts available at venBio Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Behzad Aghazadeh | Managing Team | https://shizune.co/investors/profile/behzad-aghazadeh |
| Corey Goodman | Managing Partner | https://shizune.co/investors/profile/corey-goodman |
| Richard Gaster | Managing Partner | https://shizune.co/investors/profile/richard-gaster |
| Robert Adelman | Managing Partner | https://shizune.co/investors/profile/robert-adelman |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Robert Adelman invest in?

Robert Adelman invests primarily in Medical, Health Care and Genetics startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Robert Adelman last invest?

The most recent investment recorded for Robert Adelman closed in Jun 2018. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co